Epcoritamab combined with GemOx shows deep, durable responses in transplant-ineligible relapsed/refractory diffuse large ...

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...

Innate Pharma has gained breakthrough therapy designation for lacutamab to treat adults with relapsed or refractory Sézary ...

Mechelen, Belgium Monday, February 17, 2025, 16:00 Hrs [IST] ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...